ECSP077992A - Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms - Google Patents

Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms

Info

Publication number
ECSP077992A
ECSP077992A EC2007007992A ECSP077992A ECSP077992A EC SP077992 A ECSP077992 A EC SP077992A EC 2007007992 A EC2007007992 A EC 2007007992A EC SP077992 A ECSP077992 A EC SP077992A EC SP077992 A ECSP077992 A EC SP077992A
Authority
EC
Ecuador
Prior art keywords
compounds
inhibitors
tienopirimidine
tienopiridine
derivatives
Prior art date
Application number
EC2007007992A
Other languages
English (en)
Inventor
Michael David Gaul
Christian Andrew Baumann
Kevin Douglas Kreutter
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP077992A publication Critical patent/ECSP077992A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La invención esta dirigida a tienopirimidinas y tienopiridinas de fórmula I y fórmula IIen donde R1, R3, B, Z, Q, p, q y X son como se define en la presente, el uso de dichos compuestos como moduladores de proteína tirosina cinasa, particularmente inhibidores de FLT3, el uso de dichos compuestos para reducir o inhibir la actividad cinasa de FLT3 en una célula o un sujeto, y el uso de dichos compuestos para la prevención o tratamiento en un sujeto de un trastorno proliferante celular y/o trastornos relacionados a FLT3; la presente invención se refiere además a composiciones farmacéuticas que comprenden los compuestos de la presente invención y a métodos para el tratamiento de condiciones tales como cánceres y otros trastornos proliferantes celulares.
EC2007007992A 2005-06-10 2007-12-10 Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms ECSP077992A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68971005P 2005-06-10 2005-06-10
US74694106P 2006-05-10 2006-05-10

Publications (1)

Publication Number Publication Date
ECSP077992A true ECSP077992A (es) 2008-01-23

Family

ID=37074647

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007992A ECSP077992A (es) 2005-06-10 2007-12-10 Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms

Country Status (19)

Country Link
US (3) US20060281768A1 (es)
EP (1) EP1899355A1 (es)
JP (1) JP2008543759A (es)
KR (1) KR20080021126A (es)
AR (1) AR057063A1 (es)
AU (1) AU2006258049A1 (es)
BR (1) BRPI0613644A2 (es)
CA (1) CA2611587A1 (es)
CR (1) CR9650A (es)
EA (1) EA200800011A1 (es)
EC (1) ECSP077992A (es)
IL (1) IL187689A0 (es)
MX (1) MX2007015741A (es)
NI (1) NI200700311A (es)
NO (1) NO20080162L (es)
PE (1) PE20070070A1 (es)
TW (1) TW200716651A (es)
UY (1) UY29590A1 (es)
WO (1) WO2006135639A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
JP5606734B2 (ja) 2006-04-25 2014-10-15 アステックス、セラピューティックス、リミテッド 医薬化合物
US20090124610A1 (en) * 2006-04-25 2009-05-14 Gordon Saxty Pharmaceutical compounds
WO2008039794A1 (en) * 2006-09-25 2008-04-03 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
US8193178B2 (en) 2007-09-14 2012-06-05 Janssen Pharmaceutica Nv Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
CN101861321B (zh) 2007-10-11 2013-02-06 阿斯利康(瑞典)有限公司 作为蛋白激酶b抑制剂的吡咯并[2,3-d]嘧啶衍生物
US9402847B2 (en) 2011-04-01 2016-08-02 Astrazeneca Ab Combinations comprising (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
JP5933902B2 (ja) 2011-05-13 2016-06-15 アレイ バイオファーマ、インコーポレイテッド Ｔｒｋａキナーゼ阻害剤としてのピロリジニル尿素およびピロリジニルチオ尿素化合物
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
CA2856646C (en) 2011-11-30 2020-01-14 Astrazeneca Ab Combination treatment of cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
RS59286B1 (sr) 2014-05-15 2019-10-31 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)urea kao inhibitor trka kinaze
EP3559006A4 (en) * 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
CN113874015A (zh) 2018-12-21 2021-12-31 细胞基因公司 Ripk2的噻吩并吡啶抑制剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627940B1 (en) * 1992-03-05 2003-05-07 Board of Regents, The University of Texas System Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5932765A (en) * 1997-05-23 1999-08-03 Merck Patent Gesellschaft Mit Nitromethyl ketones, process for preparing them and compositions containing them
CN1280580A (zh) * 1997-11-11 2001-01-17 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
ZA99607B (en) * 1998-01-27 1999-07-27 Rhone Poulenc Rorer Pharma Substituted oxoazaheterocyclyl factor xa inhibitors.
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
DE10110750A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR035885A1 (es) * 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
US7105505B2 (en) * 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
MXPA05001631A (es) * 2002-08-12 2005-08-19 Takeda Pharmaceutical Derivado de benceno fusionado y su uso.
JPWO2004039782A1 (ja) * 2002-10-29 2006-03-02 麒麟麦酒株式会社 Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US20060281769A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators

Also Published As

Publication number Publication date
NI200700311A (es) 2009-03-03
KR20080021126A (ko) 2008-03-06
AU2006258049A1 (en) 2006-12-21
JP2008543759A (ja) 2008-12-04
TW200716651A (en) 2007-05-01
CA2611587A1 (en) 2006-12-21
WO2006135639A1 (en) 2006-12-21
UY29590A1 (es) 2006-10-02
NO20080162L (no) 2008-03-07
MX2007015741A (es) 2008-04-29
US20060281768A1 (en) 2006-12-14
PE20070070A1 (es) 2007-03-08
CR9650A (es) 2008-09-09
BRPI0613644A2 (pt) 2011-01-25
EP1899355A1 (en) 2008-03-19
US20090163710A1 (en) 2009-06-25
US20090143378A1 (en) 2009-06-04
AU2006258049A8 (en) 2006-12-21
EA200800011A1 (ru) 2008-06-30
IL187689A0 (en) 2008-08-07
AR057063A1 (es) 2007-11-14

Similar Documents

Publication Publication Date Title
ECSP077992A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms
ECSP077998A (es) Moduladores de cinasa de aminoquinolina y aminoquinazolina
ECSP077997A (es) Moduladores de alquilquinolina y alquilquinazolina cinasa
CR9649A (es) Aminopirimidinas como modulares de cinasa
SV2008002963A (es) Triazolopiridazinas como moduladores de tirosina cinasa referencia cruzada con solicitudes relacionadas ref. prd2584sv
ECSP099662A (es) Nuevos Derivados de 3-([1,2,4]triazolo[4,3-a]piridin-7-il)benzamida
NI200700316A (es) Aminopirimidinas como moduladores de la cinasa
CR7643A (es) Derivados de 1-heterociclialquil -3-sulfonilazaindol o azaindazol como ligandos de 5-hidroxitriptamina-6
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
ECSP109953A (es) Derivados de piridazinona
GEP20125658B (en) Imidazotriazines and imidazo pyrimidines as kinase inhibitors
SV2003001148A (es) Derivados de benzamida tiazol y composciones farmaceuticas para inhibir la proliferacion de celulas, y metodos para su utilizacion ref. no.0097-01-sv
UY27714A1 (es) 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos.
BRPI0412809A (pt) compostos de sulfonildihidrobenzimidazolona como ligantes a 5-hidróxitriptamina-6
MX2010005787A (es) Derivados de imizado-tiazole en la forma de inhibidores de cinasa de proteina.
GT200600250A (es) Moduladores de quinasas con estructuras de alquilquinolina y alquilquinazolina referencia cruzada con solicitudes relacionadas
UA93609C2 (en) 2-amino-5,6-dihydro-6h-pyrrolo[3, 4-d]pyrimidine derivatives as hsp-90 inhibitors for treating cancer
UY29592A1 (es) Aminopirimidinas como moduladores de quinasas
UY29587A1 (es) Moduladores de aminoquinolina y aminoquinazolina quinasa